You are here

  • Home
  • Archive
  • Volume 16, Issue 1
  • Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised Controlled Trial
Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance

https://doi.org/10.1136/ebm1128

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests PDH provides educational, advisory and research services in association with the manufacturer of rosiglitazone.